SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB) and Door
Pharmaceuticals, LLC today announced that the companies have signed an exclusive, two-year collaboration and option
agreement focused on the development of a novel class of hepatitis B virus (HBV) core protein modulators. Door Pharmaceuticals’
innovative discovery platform targets functions of core protein distinct from viral assembly and that have the potential to interfere
with viral nucleic acid including cccDNA transcription, providing a strong complement to Assembly Bio’s current portfolio.
Read the press release here.